Skip to main content
SpringerLink
Log in

Hypertension

  • Reference work entry
  • First Online:
Principles of Diabetes Mellitus

  • 3495 Accesses

Abstract

Hypertension is a major risk factor for cardiovascular disease (CVD). Hypertension increases the risk of coronary artery disease, stroke, peripheral vascular disease, and congestive heart failure. Hypertension is twice as frequent in patients with diabetes compared to those without the disease and accounts for up to 75% of CVD risk. When hypertension coexists with diabetes, the risk of stroke or CVD is doubled and the risk for developing end-stage renal disease increases to five to six times, compared to hypertensive patients without diabetes. In this chapter we will discuss the unique aspects of hypertension in patients with diabetes along with disease mechanism and treatment. Therapy for hypertension will be discussed in the light of the new JNC 8 Guidelines published in 2014.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 699.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 899.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab. 2001;86(2):713–8.

    CAS  PubMed  Google Scholar 

  2. American Diabetes Association. Data from the National Diabetes Statistic Report (2014) http://www.diabetes.org/diabetes-basics/statistics/

  3. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000;342(13):905–12.

    Article  CAS  PubMed  Google Scholar 

  4. Lima NK, Abbasi F, Lamendola C, Reaven GM. Prevalence of insulin resistance and related risk factors for cardiovascular disease in patients with essential hypertension. Am J Hypertens. 2009;22(1):106–11.

    Article  CAS  PubMed  Google Scholar 

  5. de Boer IH, Kestenbaum B, Rue TC, Steffes MW, Cleary PA, Molitch ME, et al. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Arch Intern Med. 2008;168(17):1867–73.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, et al. Insulin resistance in essential hypertension. N Engl J Med. 1987;317(6):350–7.

    Article  CAS  PubMed  Google Scholar 

  7. Reaven GM. Relationships among insulin resistance, type 2 diabetes, essential hypertension, and cardiovascular disease: similarities and differences. J Clin Hypertens (Greenwich). 2011;13(4):238–43.

    Article  CAS  Google Scholar 

  8. Fujita T. Insulin resistance and salt-sensitive hypertension in metabolic syndrome. Nephrol Dial Transplant. 2007;22(11):3102–7.

    Article  CAS  PubMed  Google Scholar 

  9. Beatty OL, Harper R, Sheridan B, Atkinson AB, Bell PM. Insulin resistance in offspring of hypertensive parents. BMJ. 1993;307(6896):92–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Grunfeld B, Balzareti M, Romo M, Gimenez M, Gutman R. Hyperinsulinemia in normotensive offspring of hypertensive parents. Hypertension. 1994;23(1 Suppl):I12–5.

    Article  CAS  PubMed  Google Scholar 

  11. Lee CJ, Lim NK, Kim HC, Ihm SH, Lee HY, Park HY, et al. Impaired fasting glucose and impaired glucose tolerance do not predict hypertension: a community cohort study. Am J Hypertens. 2015;28(4):493–500.

    Article  PubMed  Google Scholar 

  12. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37(4):1053–9.

    Article  CAS  PubMed  Google Scholar 

  13. Draman MS, Dolan E, van der Poel L, Tun TK, McDermott JH, Sreenan S, et al. The importance of night-time systolic blood pressure in diabetic patients: Dublin Outcome Study. J Hypertens. 2015;33(7):1373–7.

    Article  CAS  PubMed  Google Scholar 

  14. Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51(1):55–61.

    Article  CAS  PubMed  Google Scholar 

  15. Eboh C, Chowdhury TA. Management of diabetic renal disease. Ann Transl Med. 2015;3(11):154.

    PubMed  PubMed Central  Google Scholar 

  16. Lee HO, Bak HJ, Shin JY, Song YM. Association between metabolic syndrome and microalbuminuria in Korean adults. Korean J Fam Med. 2015;36(2):60–71.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Zain M, Awan FR. Renin Angiotensin Aldosterone System (RAAS): its biology and drug targets for treating diabetic nephropathy. Pak J Pharm Sci. 2014;27(5):1379–91.

    CAS  PubMed  Google Scholar 

  18. Streeten DH, Auchincloss Jr JH, Anderson Jr GH, Richardson RL, Thomas FD, Miller JW. Orthostatic hypertension. Pathogenetic studies. Hypertension. 1985;7(2):196–203.

    Article  CAS  PubMed  Google Scholar 

  19. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115(3):387–97.

    Article  PubMed  Google Scholar 

  20. Balcioglu AS, Muderrisoglu H. Diabetes and cardiac autonomic neuropathy: clinical manifestations, cardiovascular consequences, diagnosis and treatment. World J Diabetes. 2015;6(1):80–91.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.

    Article  CAS  PubMed  Google Scholar 

  22. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.

    Article  CAS  PubMed  Google Scholar 

  23. Guidelines IoMUCoSfDTCP. Clinical practice guidelines we can trust. National Academy of Sciences: The national academies of sciences engineering medicine; 2011. http://iom.nationalacademies.org/Reports/2011/Clinical-Practice-Guidelines-We-Can-Trust/Standards.aspx

  24. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265(24):3255–64.

    Google Scholar 

  25. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757–64.

    Article  CAS  PubMed  Google Scholar 

  26. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–13.

    Article  PubMed Central  Google Scholar 

  27. Group AS, Cushman WC, Evans GW, Byington RP, Goff Jr DC, Grimm Jr RH, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–85.

    Article  Google Scholar 

  28. Group SR, Wright Jr JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.

    Article  Google Scholar 

  29. Cushman WC, Whelton PK, Fine LJ, et al. SPRINT TRIAL Results. Latest news in hypertension management. Hypertension. 2015;67(2):263–5.

    Google Scholar 

  30. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26 Suppl 1:S33–50.

    Google Scholar 

  31. Conlin PR, Chow D, Miller 3rd ER, Svetkey LP, Lin PH, Harsha DW, et al. The effect of dietary patterns on blood pressure control in hypertensive patients: results from the Dietary Approaches to Stop Hypertension (DASH) trial. Am J Hypertens. 2000;13(9):949–55.

    Article  CAS  PubMed  Google Scholar 

  32. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344(1):3–10.

    Article  CAS  PubMed  Google Scholar 

  33. American Heart Association. Recommendations for physical activity in adults (Healthy Living) (2014). http://www.heart.org/HEARTORG/HealthyLiving/PhysicalActivity/FitnessBasics/American-Heart-Association-Recommendations-for-Physical-Activity-in-Adults_UCM_307976_Article.jsp#.VsPyvUvE38E

  34. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456–62.

    Article  CAS  PubMed  Google Scholar 

  35. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355(9200):253–9.

    Article  Google Scholar 

  36. Investigators DT, Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, et al. Effect of Ramipril on the incidence of diabetes. N Engl J Med. 2006;355(15):1551–62.

    Article  Google Scholar 

  37. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 Suppl):169S–73.

    Article  CAS  PubMed  Google Scholar 

  38. Sato A, Fukuda S. A prospective study of frequency and characteristics of cough during ACE inhibitor treatment. Clin Exp Hypertens. 2015;37(7):563–8.

    Google Scholar 

  39. Brugts JJ, Arima H, Remme W, Bertrand M, Ferrari R, Fox K, et al. The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease. Int J Cardiol. 2014;176(3):718–23.

    Article  CAS  PubMed  Google Scholar 

  40. Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol. 2003;3(3):311–7.

    Article  CAS  PubMed  Google Scholar 

  41. Loftus PA, Tan M, Patel G, Lin J, Helman S, Badhey A, et al. Risk factors associated with severe and recurrent angioedema: an epidemic linked to ACE-inhibitors. Laryngoscope. 2014;124(11):2502–7.

    Article  PubMed  Google Scholar 

  42. Johnson ES, Weinstein JR, Thorp ML, Platt RW, Petrik AF, Yang X, et al. Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril. Pharmacoepidemiol Drug Saf. 2010;19(3):266–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160(5):685–93.

    Article  CAS  PubMed  Google Scholar 

  44. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109(11):1417–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49(11):1157–63.

    Article  CAS  PubMed  Google Scholar 

  46. Birkenhager WH, Staessen JA. Dual inhibition of the renin system by aliskiren and valsartan. Lancet. 2007;370(9583):195–6.

    Article  PubMed  Google Scholar 

  47. Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25(1):217–26.

    Article  CAS  PubMed  Google Scholar 

  48. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204–13.

    Article  CAS  PubMed  Google Scholar 

  49. Kaplan NM. Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence. Ann Intern Med. 2001;135(12):1079–83.

    Article  CAS  PubMed  Google Scholar 

  50. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–9.

    Article  CAS  PubMed  Google Scholar 

  51. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–8.

    Article  CAS  PubMed  Google Scholar 

  52. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003.

    Article  CAS  PubMed  Google Scholar 

  53. Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165(12):1401–9.

    Article  CAS  PubMed  Google Scholar 

  54. Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2006;166(20):2191–201.

    Article  CAS  PubMed  Google Scholar 

  55. de la Sierra A. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. J Hum Hypertens. 2009;23(8):503–11.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Diabetes and Hypertension, State University of New York, Downstate Medical Center and Kings County Hospital Center, Brooklyn, NY, USA

    Lisel Hope, Judith Giunta, Nathaniel Winer & Samy I. McFarlane

  2. Endocrinology, Pacific Nephrology Associates, Tacoma, WA, USA

    Ho Won Lee

  3. Endocrinology, SUNY Downstate Medical Center, Center Valley, PA, USA

    Sara Choudhry

Authors
  1. Lisel Hope
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Judith Giunta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nathaniel Winer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ho Won Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sara Choudhry
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Samy I. McFarlane
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samy I. McFarlane .

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Gerald J. Friedman Diabetes Institute, Lenox Hill Hospital, Hofstra Northwell School of Medicine, Northwell Health, New York, New York, USA

    Leonid Poretsky

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this entry

Cite this entry

Hope, L., Giunta, J., Winer, N., Won Lee, H., Choudhry, S., McFarlane, S.I. (2017). Hypertension. In: Poretsky, L. (eds) Principles of Diabetes Mellitus. Springer, Cham. https://doi.org/10.1007/978-3-319-18741-9_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-18741-9_31

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-18740-2

  • Online ISBN: 978-3-319-18741-9

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation